Abstract
Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet, seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of the immune system within the central nervous system (CNS) and altered the paradigm for successful immunotherapy. The impact of standard therapies on the response to immunotherapy is now better understood, as well. This new knowledge has implications for a broad range of tumours that develop within the CNS. Nevertheless, the requirements for successful therapy remain effective delivery and target specificity, while the dramatic heterogeneity of malignant gliomas at the genetic and immunological levels remains a profound challenge.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7, 392–401 (2006).
Walker, M. D. et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323–1329 (1980).
Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
Imperato, J. P., Paleologos, N. A. & Vick, N. A. Effects of treatment on long-term survivors with malignant astrocytomas. Ann. Neurol. 28, 818–822 (1990).
Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699–708 (2014).
Stupp, R. et al. LTBK-01: prospective, multi-center phase III trial Tumor Treating Fields together temozolomide compared temozolomide alone patients newly diagnosed glioblastoma. Neuro Oncol. 18 (Suppl. 6), i1 (2016).
Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306–2316 (2017).
Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014). This study provides one of the most thorough documentations to date of glioblastoma heterogeneity at the single-cell level.
Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
Engelhardt, B., Vajkoczy, P. & Weller, R. O. The movers and shapers in immune privilege of the CNS. Nat. Immunol. 18, 123–131 (2017).
Medawar, P. B. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29, 58–69 (1948). This landmark paper is often credited as the first to suggest the notion of CNS immune privilege.
Bradbury, M. W. & Westrop, R. J. Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. J. Physiol. 339, 519–534 (1983).
Cserr, H. F. & Knopf, P. M. Cervical lymphatics, the blood–brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today 13, 507–512 (1992).
Goldmann, J. et al. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J. Leukoc. Biol. 80, 797–801 (2006).
Widner, H. et al. Scintigraphic method to quantify the passage from brain parenchyma to the deep cervical lymph nodes in rats. Eur. J. Nucl. Med. 13, 456–461 (1987).
Aspelund, A. et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991–999 (2015).
Louveau, A. et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci. 21, 1380–1391 (2018).
Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337–341 (2015).
Eide, P. K., Vatnehol, S. A. S., Emblem, K. E. & Ringstad, G. Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes. Sci. Rep. 8, 7194 (2018).
Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl. Med. 4, 147ra111 (2012). This research was the first to document the existence of the glymphatic pathway.
Kipnis, J. Multifaceted interactions between adaptive immunity and the central nervous system. Science 353, 766–771 (2016).
Bechmann, I., Galea, I. & Perry, V. H. What is the blood–brain barrier (not)? Trends Immunol. 28, 5–11 (2007).
Huber, J. D., Egleton, R. D. & Davis, T. P. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 24, 719–725 (2001).
Tietz, S. & Engelhardt, B. Brain barriers: crosstalk between complex tight junctions and adherens junctions. J. Cell Biol. 209, 493–506 (2015).
Owens, T., Bechmann, I. & Engelhardt, B. Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 67, 1113–1121 (2008). Along with Aspelund et al. (2015), this is the first study to characterize CNS lymphatic vessels within the meninges.
Andersson, P. B., Perry, V. H. & Gordon, S. The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. Neuroscience 48, 169–186 (1992).
Schlager, C. et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature 530, 349–353 (2016).
Zamvil, S. S. & Steinman, L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8, 579–621 (1990).
Long, D. M. Capillary ultrastructure and the blood–brain barrier in human malignant brain tumors. J. Neurosurg. 32, 127–144 (1970).
Vajkoczy, P. & Menger, M. D. Vascular microenvironment in gliomas. J. Neurooncol. 50, 99–108 (2000).
Watkins, S. et al. Disruption of astrocyte–vascular coupling and the blood-brain barrier by invading glioma cells. Nat. Commun. 5, 4196 (2014).
Li, Q. & Barres, B. A. Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol. 18, 225–242 (2018).
Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841–845 (2010).
Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M. & Rossi, F. M. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 14, 1142–1149 (2011).
Bennett, F. C. et al. A combination of ontogeny and CNS environment establishes microglial identity. Neuron 98, 1170–1183 e1178 (2018).
Chongsathidkiet, P. et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 24, 1459–1468 (2018). This research uncovers the novel phenomenon of T cell sequestration within the bone marrow. The phenomenon is specific to tumours of the intracranial compartment and suggests a novel mechanism for CNS-imposed limitations to T cell access that tumours can usurp.
Fecci, P. E., Heimberger, A. B. & Sampson, J. H. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin. Cancer Res. 20, 5620–5629 (2014).
Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013).
Gajewski, T. F. et al. Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. Adv. Exp. Med. Biol. 1036, 19–31 (2017).
Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019). This study highlights some issues associated with using the neoantigen vaccine strategy for glioblastoma.
Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326–341 (2017). This excellent review article includes an in-depth discussion of the brain tumour microenvironment, relevant cell types, potential tumour-promoting mechanisms and possible therapeutics.
Perng, P. & Lim, M. Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front. Oncol. 5, 153 (2015).
Vitkovic, L., Maeda, S. & Sternberg, E. Anti-inflammatory cytokines: expression and action in the brain. Neuroimmunomodulation 9, 295–312 (2001).
Gong, D. et al. TGFbeta signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 13, 31 (2012).
Wainwright, D. A. et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18, 6110–6121 (2012).
Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269–1274 (2003).
Zhang, I. et al. Characterization of arginase expression in glioma-associated microglia and macrophages. PLOS ONE 11, e0165118 (2016).
Hawkins, R. A., O'Kane, R. L., Simpson, I. A. & Vina, J. R. Structure of the blood–brain barrier and its role in the transport of amino acids. J. Nutr. 136, 218S–226S (2006).
Bogdahn, U. et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 13, 132–142 (2011).
den Hollander, M. W. et al. TGF-beta antibody uptake in recurrent high-grade glioma imaged with 89Zr-fresolimumab PET. J. Nucl. Med. 56, 1310–1314 (2015).
Brandes, A. A. et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 18, 1146–1156 (2016).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02502708 (2015).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02052648 (2014).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02327078 (2014).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02752074 (2016).
Long, G. V. et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. J. Clin. Oncol. 36, 108–108 (2018).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02903914 (2016).
Graeber, M. B., Scheithauer, B. W. & Kreutzberg, G. W. Microglia in brain tumors. Glia 40, 252–259 (2002).
Chen, Z. et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res. 77, 2266–2278 (2017).
Bowman, R. L. et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. 17, 2445–2459 (2016).
Zhou, W. et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 17, 170–182 (2015).
Hambardzumyan, D., Gutmann, D. H. & Kettenmann, H. The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 19, 20–27 (2016).
Komohara, Y., Ohnishi, K., Kuratsu, J. & Takeya, M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216, 15–24 (2008).
Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14–20 (2014).
Majety, M., Runza, V., Lehmann, C., Hoves, S. & Ries, C. H. A drug development perspective on targeting tumor-associated myeloid cells. FEBS J. 285, 763–776 (2018).
Hume, D. A. & MacDonald, K. P. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119, 1810–1820 (2012).
Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264–1272 (2013).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT01349036 (2011).
Butowski, N. et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 18, 557–564 (2016).
Germano, G. et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249–262 (2013).
Vakilian, A., Khorramdelazad, H., Heidari, P., Sheikh Rezaei, Z. & Hassanshahi, G. CCL2/CCR2 signaling pathway in glioblastoma multiforme. Neurochem. Int. 103, 1–7 (2017).
Vonderheide, R. H. & Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035–1043 (2013).
Kaneda, M. M. et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).
Weiskopf, K. Cancer immunotherapy targeting the CD47/SIRPalpha axis. Eur. J. Cancer 76, 100–109 (2017).
Kwong, L. S., Brown, M. H., Barclay, A. N. & Hatherley, D. Signal-regulatory protein alpha from the NOD mouse binds human CD47 with an exceptionally high affinity—implications for engraftment of human cells. Immunology 143, 61–67 (2014).
Hodges, T. R. et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 19, 1047–1057 (2017).
Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206–2211 (2016).
Muscat, A. M. et al. The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection. Oncotarget 9, 7844–7858 (2018).
Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189–193 (2014).
Barthel, F. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature (in the press).
Kim, H. et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 25, 316–327 (2015).
Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768–776 (2016).
Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598–2608 (2017).
Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
Hellmann, M. D. et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33, 843–852.e844 (2018).
Therkildsen, C. et al. Glioblastomas, astrocytomas and oligodendrogliomas linked to Lynch syndrome. Eur. J. Neurol. 22, 717–724 (2015).
Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004).
Marty Pyke, R. et al. Evolutionary pressure against MHC class II binding cancer mutations. Cell 175, 416–428.e413 (2018).
McGranahan, N. et al. Allele-Specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 e1211 (2017).
Wang, Q. et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32, 42–56 e46 (2017).
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002).
Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462–469 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03718767 (2018).
Bigner, S. H. et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 50, 8017–8022 (1990).
Humphrey, P. A. et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl Acad. Sci. USA 87, 4207–4211 (1990).
Wikstrand, C. J., McLendon, R. E., Friedman, A. H. & Bigner, D. D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 57, 4130–4140 (1997).
Padfield, E., Ellis, H. P. & Kurian, K. M. Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. Front. Oncol. 5, 5 (2015).
Migliorini, D. et al. CAR T-Cell Therapies in glioblastoma: a first look. Clin. Cancer Res. 24, 535–540 (2018).
O'Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).
Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019).
Cloughesy, T. F. et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci. Transl. Med. 8, 341ra375 (2016).
Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150–161 (2018).
Fountzilas, C., Patel, S. & Mahalingam, D. Review: oncolytic virotherapy, updates and future directions. Oncotarget 8, 102617–102639 (2017).
Lang, F. F. et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 36, 1419–1427 (2018).
Markert, J. M. et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol. Ther. 22, 1048–1055 (2014).
Cai, J. et al. Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. Oncotarget 6, 18105–18115 (2015).
Gusyatiner, O. & Hegi, M. E. Glioma epigenetics: from subclassification to novel treatment options. Semin. Cancer Biol. 51, 50–58 (2018).
Hassan, A., Mosley, J., Singh, S. & Zinn, P. O. A comprehensive review of genomics and noncoding RNA in gliomas. Top. Magn. Reson. Imaging 26, 3–14 (2017).
Johann, P. D. et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 29, 379–393 (2016).
Mao, C. X. et al. The molecular classification of astrocytic tumors. Oncotarget 8, 96340–96350 (2017).
Loo Yau, H., Ettayebi, I. & De Carvalho, D. D. The cancer epigenome: exploiting its vulnerabilities for immunotherapy. Trends Cell Biol. 29, 31–43 (2019).
Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770–775 (2018).
Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018).
Shu, X. S. et al. The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid-inducible gene-I-like receptor signalling and is a potential prognostic biomarker for colon cancer. J. Pathol. 244, 36–48 (2018).
Shen, J. et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat. Med. 24, 556–562 (2018).
Amankulor, N. M. et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 31, 774–786 (2017).
Kohanbash, G. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Invest. 127, 1425–1437 (2017).
Zhang, X. et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol. 18, 1402–1412 (2016).
Su, Y. B. et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J. Clin. Oncol. 22, 610–616 (2004).
Sampson, J. H. et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 13, 324–333 (2011).
Fadul, C. E. et al. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol. 13, 393–400 (2011).
Grossman, S. A. et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J. Natl Compr. Canc. Netw. 13, 1225–1231 (2015).
Batich, K. A. et al. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin. Cancer Res. 23, 1898–1909 (2017).
Asavaroengchai, W., Kotera, Y. & Mule, J. J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl Acad. Sci. USA 99, 931–936 (2002).
Nistico, P. et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int. J. Cancer 124, 130–139 (2009).
Schaaf, M. B., Garg, A. D. & Agostinis, P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 9, 115 (2018).
Yang, J., Yan, J. & Liu, B. Targeting VEGF/VEGFR to Modulate Antitumor Immunity. Front. Immunol. 9, 978 (2018).
Manzoni, M. et al. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 79, 187–196 (2010).
Martino, E. C. et al. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov. 2, 16025 (2016).
Larkin, J., Hodi, F. S. & Wolchok, J. D. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 1270–1271 (2015).
Robert, C. et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).
Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016).
Immunotherapy Timeline of Progress, https://www.cancerresearch.org/immunotherapy/timeline-of-progress (2019).
Agarwalla, P., Barnard, Z., Fecci, P., Dranoff, G. & Curry, W. T. Jr Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J. Immunother. 35, 385–389 (2012).
Fecci, P. E. et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 13, 2158–2167 (2007). This study is the first to preclinically test immune checkpoint blockade in a brain tumour model.
Antonios, J. P. et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight 1, e87059 (2016).
Reardon, D. A. et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol. Res. 4, 124–135 (2016).
Wainwright, D. A. et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20, 5290–5301 (2014).
Zeng, J. et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86, 343–349 (2013).
Filley, A. C., Henriquez, M. & Dey, M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 8, 91779–91794 (2017).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02617589 (2015).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02667587 (2016).
Wu, A. et al. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. J. Neurooncol. 143, 241–249 (2019).
Woroniecka, K. et al. T-Cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin. Cancer Res. 24, 4175–4186 (2018). This study is the first to reveal and characterize the severity of bona fide T cell exhaustion in patients with glioblastoma.
Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 379, 722–730 (2018).
Brooks, W. H., Caldwell, H. D. & Mortara, R. H. Immune responses in patients with gliomas. Surg. Neurol. 2, 419–423 (1974).
Brooks, W. H., Roszman, T. L. & Rogers, A. S. Impairment of rosette-forming T lymphocytes in patients with primary intracranial tumors. Cancer 37, 1869–1873 (1976).
Fecci, P. E. et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66, 3294–3302 (2006). This publication is the first to demonstrate the systemic immune impact of Treg cells in patients with glioblastoma.
Dunn, G. P., Fecci, P. E. & Curry, W. T. Cancer immunoediting in malignant glioma. Neurosurgery 71, 201–222; discussion 222–223 (2012).
Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A. & Fecci, P. E. T-cell dysfunction in glioblastoma: applying a new framework. Clin. Cancer Res. 24, 3792–3802 (2018).
Dix, A. R., Brooks, W. H., Roszman, T. L. & Morford, L. A. Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol. 100, 216–232 (1999).
Brooks, W. H., Netsky, M. G., Normansell, D. E. & Horwitz, D. A. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. 136, 1631–1647 (1972).
Roszman, T. L. & Brooks, W. H. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin. Exp. Immunol. 39, 395–402 (1980).
Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501 (2016).
Chauvin, J. M. et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J. Clin. Invest. 125, 2046–2058 (2015).
Blackburn, S. D. et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29–37 (2009).
Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917–927 (2012).
Kurtulus, S. et al. TIGIT predominantly regulates the immune response via regulatory T cells. J. Clin. Invest. 125, 4053–4062 (2015).
Angelosanto, J. M., Blackburn, S. D., Crawford, A. & Wherry, E. J. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J. Virol. 86, 8161–8170 (2012).
Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015).
Kim, J. E. et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin. Cancer Res. 23, 124–136 (2017).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02658981 (2016).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02817633 (2016).
Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477–486 (2019). This report describes the first trial to show the efficacy of immune checkpoint blockade in patients with glioblastoma, which was accomplished via simple neoadjuvant administration prior to resection of recurrent tumours.
Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. 25, 470–476 (2019).
Law, T. M. et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824–832 (1995).
Rosenberg, S. A. & Dudley, M. E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl Acad. Sci. USA 101, 14639–14645 (2004).
Schuessler, A. et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 74, 3466–3476 (2014).
Cobbs, C. S. et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62, 3347–3350 (2002).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02661282 (2016).
Maus, M. V., Grupp, S. A., Porter, D. L. & June, C. H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625–2635 (2014).
Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094–1101 (2017).
Brown, C. E. et al. Bioactivity and safety of IL13R alpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062–4072 (2015).
Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561–2569 (2016).
Long, K. B. et al. CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success. Front. Immunol. 9, 2740 (2018).
Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473–488 e476 (2019). This article describes a preclinical study in which the expression of CD40L on CAR T cells led to the killing of antigen-negative tumour cells and the elimination of tumour immune escape via antigen loss.
Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049–1058 (2019).
Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563–571 (2018). This study identifies predictors of clinical response to CAR T cell therapy as being exclusively intrinsic properties of the administered cells.
Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307–312 (2018). This case report describes how fortuitous deletion of the TET2 gene by CARs led to complete remission of CLL.
Ichiyama, K. et al. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 42, 613–626 (2015).
Shlush, L. I. Age-related clonal hematopoiesis. Blood 131, 496–504 (2018).
Carty, S. A. et al. The loss of TET2 promotes CD8+ T cell memory differentiation. J. Immunol. 200, 82–91 (2018).
Cull, A. H., Snetsinger, B., Buckstein, R., Wells, R. A. & Rauh, M. J. Tet2 restrains inflammatory gene expression in macrophages. Exp. Hematol. 55, 56–70 e13 (2017).
Zhang, Q. et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525, 389–393 (2015).
Chheda, Z. S. et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J. Exp. Med. 215, 141–157 (2018).
Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat. Med. 24, 572–579 (2018).
Sampson, J. H. et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722–4729 (2010).
Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).
Oji, Y. et al. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int. J. Cancer 139, 1391–1401 (2016).
Rampling, R. et al. A cancer research UK first time in human phase I Trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin. Cancer Res. 22, 4776–4785 (2016).
Pollack, I. F. et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic–polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J. Clin. Oncol. 32, 2050–2058 (2014).
Liau, L. M. et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11, 5515–5525 (2005).
Prins, R. M. et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Cancer Res. 17, 1603–1615 (2011).
Okada, H. et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29, 330–336 (2011).
Phuphanich, S. et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol. Immunother. 62, 125–135 (2013).
Wen, P. Y. et al. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. J. Clin. Oncol. 32, 2005–2005 (2014).
Liau, L. M. et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J. Transl. Med. 16, 142 (2018).
Van Brussel, I., Berneman, Z. N. & Cools, N. Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system. Mediators Inflamm. 2012, 690643 (2012).
Mailliard, R. B. et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64, 5934–5937 (2004).
Mitchell, D. A. et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519, 366–369 (2015). This study demonstrates that the activation of memory T cells prior to DC vaccination leads to increased migration of DCs to lymph nodes and improved clinical responses.
Garg, A. D., Coulie, P. G., Van den Eynde, B. J. & Agostinis, P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. 38, 577–593 (2017).
Nandu, H., Wen, P. Y. & Huang, R. Y. Imaging in neuro-oncology. Ther. Adv. Neurol. Disord. 11, 1756286418759865 (2018).
Aquino, D., Gioppo, A., Finocchiaro, G., Bruzzone, M. G. & Cuccarini, V. MRI in glioma immunotherapy: evidence, pitfalls, and perspectives. J. Immunol. Res. 2017, 5813951 (2017).
Park, J. et al. Immune checkpoint inhibitor-induced reinvigoration of tumor-infiltrating CD8+ T cells is determined by their differentiation status in glioblastoma. Clin. Cancer Res. 25, 2549–2559 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03068832 (2017).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT04015700 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03422094 (2018).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03726515 (2018).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03638167 (2018).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03500991 (2018).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02442297 (2015).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02208362 (2014).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03299309 (2017).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02529072 (2015).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT02193347 (2014).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03223103 (2017).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03914768 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03149003 (2017).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT01204684 (2010).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03927222 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03688178 (2018).
Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249–253 (2015).
Johnson, L. A., Sanchez-Perez, L., Suryadevara, C. M. & Sampson, J. H. Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. Oncoimmunology 3, e944059 (2014).
Farber, S. H. et al. Embracing rejection: immunologic trends in brain metastasis. Oncoimmunology 5, e1172153 (2016).
Fischer, G. M. et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 9, 628–645 (2019).
Badie, B. & Schartner, J. M. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46, 957–961; discussion 961–962 (2000).
Bloch, O. et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin. Cancer Res. 19, 3165–3175 (2013).
Parney, I. F., Waldron, J. S. & Parsa, A. T. Flow cytometry and in vitro analysis of human glioma-associated macrophages: laboratory investigation. J. Neurosurg. 110, 572–582 (2009).
Sugihara, A. Q., Rolle, C. E. & Lesniak, M. S. Regulatory T cells actively infiltrate metastatic brain tumors. Int. J. Oncol. 34, 1533–1540 (2009).
Berghoff, A. S. et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 66, 289–299 (2015).
Acknowledgements
This work was supported by grants from the National Institutes of Health to J.H.S.: R01-NS099463, P50-CA190991, P30-CA14236, P01-CA225622, R01-CA235612, U01-NS090284, R01-NS085412 and R01-CA175517. The funders had no role in the preparation of the manuscript or the decision to publish. The authors acknowledge T. Wright for her assistance with manuscript preparation.
Author information
Authors and Affiliations
Contributions
All authors provided substantial contributions to the discussions of the content, made significant contributions to the writing of the article and contributed equally to the review and editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
J.H.S. has an equity interest in Annias Immunotherapeutics, which has licensed intellectual property from Duke related to the use of the PEP-CMV vaccine in the treatment of glioblastoma. J.H.S. has an equity interest in Istari Oncology, which has licensed intellectual property from Duke related to the use of polio virus and D2C7 in the treatment of glioblastoma. J.H.S. has additional relationships with Celldex (intellectual property, royalties) and Medicenna Therapeutics (consulting). J.H.S. is an inventor on patents related to the PEP-CMV DC vaccine with tetanus, as well as to polio virus vaccine and D2C7 in the treatment of glioblastoma. D.M.A is an inventor on patents related to the use of polio virus. M.D.G is an inventor on patents related to cellular vaccines. Duke and certain Duke investigators could benefit financially if related therapies prove effective and are commercially successful. P.E.F. has no relevant disclosures.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Tumour-treating fields
-
(TTFields). External application of alternating electrical fields to disrupt the multiplication of tumour cells.
- Glial–lymphatic (glymphatic) pathway
-
A recently characterized functional waste clearance pathway in the central nervous system that connects the brain interstitium to the cerebrospinal fluid spaces via aquaporin channels.
- Glia limitans
-
A thin barrier of astrocyte foot processes associated with the parenchymal basal lamina surrounding the brain and spinal cord. The glia limitans plays a crucial role in regulating the movement of small molecules and cells into the brain parenchyma.
- Microglia
-
The resident self-renewing population of macrophages in the central nervous system.
- Lynch syndrome
-
Also known as hereditary non-polyposis colorectal cancer. A type of inherited cancer syndrome associated with a genetic predisposition to different cancer types, including glioblastoma.
- Myelosuppression
-
A condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells and platelets.
- Lymphopenia
-
The condition of having an abnormally low level of lymphocytes in the blood.
- Lymphokine-activated killer (LAK) cells
-
Lymphocytes cultured in the presence of interleukin-2 (IL-2) to stimulate their cytotoxic activity.
- Pseudoprogression
-
A new or enlarging area of contrast agent enhancement occurring early after the end of radiotherapy or immunotherapy (for example, within 3–4 months), in the absence of true tumour growth, that subsides or stabilizes without a change in therapy.
Rights and permissions
About this article
Cite this article
Sampson, J.H., Gunn, M.D., Fecci, P.E. et al. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 20, 12–25 (2020). https://doi.org/10.1038/s41568-019-0224-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-019-0224-7
This article is cited by
-
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Journal of Hematology & Oncology (2024)
-
Immune cell infiltration and inflammatory landscape in primary brain tumours
Journal of Translational Medicine (2024)
-
Spatial transcriptomics reveals segregation of tumor cell states in glioblastoma and marked immunosuppression within the perinecrotic niche
Acta Neuropathologica Communications (2024)
-
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Journal of Translational Medicine (2024)
-
ZDHHC5-mediated S-palmitoylation of FAK promotes its membrane localization and epithelial-mesenchymal transition in glioma
Cell Communication and Signaling (2024)